Novo Nordisk's shares recovered some ground on Monday after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema, but ...
On this week's overreaction pod, Dan Wetzel Ross Dellenger and SI's Pat Forde acknowledge what led to home teams handedly winning each matchup. They cover how offensive line and defensive line play ...